Related Experiment Video
Updated: May 24, 2026
07:01
Electrophoretic Delivery of γ-aminobutyric Acid (GABA) into Epileptic Focus Prevents Seizures in Mice
Published on: May 16, 2019
Interactions between antiepileptics and second-generation antipsychotics
Jose de Leon1, Vincenza Santoro, Concetta D'Arrigo
1University of Kentucky Mental Health Research Center at Eastern State Hospital, 627 West Fourth St., Lexington, KY 40508, USA. jdeleon@uky.edu
Expert Opinion on Drug Metabolism & Toxicology
|February 16, 2012
Summary
Drug interactions between antiepileptics (AEDs) and second-generation antipsychotics (SGAPs) are common. Understanding these pharmacokinetic and pharmacodynamic interactions is crucial for safe and effective treatment, especially in bipolar disorder.
Area of Science:
- Pharmacology
- Neuroscience
- Clinical Pharmacy
Background:
- Drug interactions between antiepileptics (AEDs) and second-generation antipsychotics (SGAPs) can impact treatment efficacy and safety.
- Mechanisms of some pharmacodynamic interactions between AEDs and SGAPs are not fully understood.
- Combinations of AEDs and SGAPs are frequently used for comorbid conditions, particularly in bipolar disorder.
Purpose of the Study:
- To provide a comprehensive review of pharmacokinetic and pharmacodynamic drug interactions between AEDs and SGAPs.
- To highlight the newest drug pharmacokinetics relevant to these interactions.
- To identify areas requiring further research and clinical attention.
Main Methods:
- Comprehensive literature review of pharmacokinetic and pharmacodynamic drug interaction studies.
- Analysis of existing data on AED-SGAP combinations.
- Synthesis of findings to inform clinical practice and future research.
Main Results:
- Pharmacokinetic interactions, particularly induction by certain AEDs, necessitate dosing adjustments for SGAPs.
- Limited but important pharmacodynamic interactions exist, with some offering benefits (e.g., additive effects in bipolar disorder, weight gain reduction) and others posing risks (e.g., sedation, weight gain, osteoporosis, pancreatitis, agranulocytosis).
- Specific combinations require further investigation due to potential interactions.
Conclusions:
- Dosing adjustments and therapeutic drug monitoring are recommended for specific AED-SGAP combinations to mitigate pharmacokinetic interactions.
- Further research is essential to clarify the clinical relevance of numerous AED-SGAP combinations.
- Collaboration among various stakeholders is crucial for advancing the understanding and safe use of these drug combinations.
Related Concept Videos
01:21Antipsychotic Drugs: Typical and Atypical Agents
Antipsychotic drugs are classified into first-generation (typical) drugs including phenothiazines; and second-generation (atypical) drugs. Chlorpromazine hydrochloride (Thorazine), a phenothiazine derivative, broadly impacts the central, autonomic, and endocrine systems. This drug, along with typical agents like haloperidol (Haldol), primarily works by antagonizing D2 receptors, thus reducing dopaminergic neurotransmission. However, typical antipsychotics can cause side effects such as sedation...
01:08Antiepileptic Drugs: Sodium Channel Blockers
Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
01:28Psychosis and Antipsychotic Drugs: Overview
The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic symptoms in all...
01:21Antipsychotic Drugs: Therapeutic Uses and Side Effects
Antipsychotic drugs primarily block dopamine and serotonin receptors and cholinergic, adrenergic, and histaminergic receptors, thereby reducing hallucinations and delusions in conditions like schizophrenia. However, they can trigger unwanted extrapyramidal effects such as dystonias, Parkinson-like symptoms, and tardive dyskinesia.
Despite these side effects, antipsychotics are used therapeutically for various purposes, including managing schizophrenia, preventing nausea and vomiting, curbing...
Despite these side effects, antipsychotics are used therapeutically for various purposes, including managing schizophrenia, preventing nausea and vomiting, curbing...
01:14Antiepileptic Drugs: Glutamate Antagonists
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...